Attana AB

We provide world-class analytical instruments and services for validating, selecting and optimizing drug candidates. For our track record of 75+ analyzed candidates we have so far improved the overall clinical trial success rate by more than 4x. By accurately classifying candidates prior to clinical trials, we allow pharmaceutical companies to focus on the most promising candidates, increasing their efficiency and profitability.

Attana was founded with the vision of in vitro characterization of molecular interactions, mimicking in vivo conditions. We have developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. We are also developing the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool, for e.g. SARS-CoV-2 testing and immunity profiling.